Yuto Torii started out as a veterinarian before working in pharma sales and strategy at Eli Lilly and Elanco, giving him a background that spans clinical, commercial, and operating experience in life sciences that few investors have. He now focuses on biotech, medical device, and animal-health startups, taking hands-on board roles at companies like Neusignal Therapeutics, Vetanic, and LIFESCAPES while also advising Sapporo City on bio-business and judging Keio's healthcare venture contests.
About their Fund
Keio Innovation Initiative was the first impact fund among university-affiliated VCs in Japan, expanding beyond Keio-originated research to back deep-tech startups from other universities and research institutes in fields like regenerative medicine, AI, and health, while building out a formal impact strategy—including a Theory of Change, impact measurement, and shared KPIs with startups—from due diligence through execution. Backed by an unusually large group of investors, including Keio, Nomura, Japan Post Insurance, and major banks and insurers, and led by a CEO with a background spanning journalism, startup operations, and university governance, the fund supports technically complex startups from the lab stage through post-listing, aiming to advance quality of life, social systems, and environmental protection.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































